Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil.
Samaira YounisCasper E ChristensenNikolaj M ToftThomas SøborgFaisal M AminAnders HougaardMessoud AshinaPublished in: Cephalalgia : an international journal of headache (2019)
A majority of patients developed migraine after both calcitonin gene-related peptide and sildenafil. This supports the hypothesis that the cyclic adenosine monophosphate and cyclic guanosine monophosphate intracellular signaling pathways in migraine induction converge in a common cellular determinator, which ultimately triggers the same attacks. Trial registration: ClinicalTrials.gov Identifier: NCT03143465.
Keyphrases
- end stage renal disease
- pulmonary hypertension
- newly diagnosed
- ejection fraction
- pulmonary arterial hypertension
- copy number
- signaling pathway
- chronic kidney disease
- clinical trial
- prognostic factors
- peritoneal dialysis
- study protocol
- genome wide identification
- phase iii
- dna methylation
- gene expression
- patient reported outcomes
- reactive oxygen species
- phase ii
- pi k akt
- induced apoptosis
- single molecule
- open label